As the government shutdown dragged on, some corporate practices at law firms have been financially squeezed, unable to collect fees from stalled initial public offerings. Meanwhile, some capital markets practices at law firms took creative approaches to work around the Securities and Exchange Commission’s gutted operations.

In a rare event, a biotechnology firm Gossamer Bio on Wednesday disclosed pricing details for a $230 million initial public offering without explicit SEC approval. The company is represented by Latham & Watkins, led by partner Matthew Bush, while Cooley, led by Charles Kim, represents the underwriters.